Emcure Pharma Listing: Strong Start, Caution Ahead

Shivani Nyati, Head of Wealth at Swastika Investmart Ltd, expressed that the oversubscription and listing gain reflect investor confidence in Emcure's established brand, diversified product range, and global market presence. However, she noted that the pharmaceutical industry's regulatory challenges and potential supply chain disruptions remain areas of concern. While Emcure Pharma's listing performance has been strong and met pre-listing expectations, Nyati advised investors to be mindful of these risks. She recommended that investors maintain their positions, with a stop loss set at ₹1200, to safeguard against volatility.

‍

‍

‍